4 completed, 2 terminated, 1 active not recruiting, 1 unknown. 8 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Terminated 2, Active not recruiting 1, Unknown 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Sandostatin: new trials by email Literature Review of Sandostatin trials Research Report on Sandostatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas Sacituzumab Govitecan, EKG, Brain MRI - Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2025-06-09 | 2026-01-21 |
| Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber Octreotide LAR - Hereditary Hemorrhagic Telangiectasia, Gastrointestinal Hemorrhage | Phase 2 | Unknown | Radboud University Medical Center | 15 | 2016-10-01 | 2018-04-20 |
| Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients Octreotide - Octreotide, Sputum | Phase 2 | Completed | Danbury Hospital | 5 | 2016-09-01 | 2020-10-08 |
| Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Bevacizumab, Everolimus, Octreotide Acetate - Advanced Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 150 | 2010-10-15 | 2022-08-04 |
| AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors AMG 706, octreotide - Gastrointestinal Carcinoid Tumor, Islet Cell Tumor | Phase 2 | Completed | Eastern Cooperative Oncology Group | 46 | 2008-11-07 | 2023-07-05 |
| Sandostatin for Patients With Androgen Independent Prostate Cancer Sandostatin - Prostate Cancer | Phase 2 | Terminated | University of California, San Francisco | 13 | 2007-07-01 | 2013-12-11 |
| Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer octreotide acetate - Liver Cancer | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 31 | 2005-07-01 | 2012-02-14 |
| Treatment of Orthostatic Intolerance Acetazolamide, Atomoxetine, NO Drug - Tachycardia, Chronic Orthostatic Intolerance | Phase 1 / Phase 2 | Active not recruiting | Satish R. Raj | 150 | 1997-04-01 | 2026-10-16 |
Vipoma (2) · Adenoma, Islet Cell (1) · Anemia (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Islet Cell (1) · Gastrinoma (1) · Gastrointestinal Hemorrhage (1) · Glucagonoma (1) · Insulinoma (1) · Liver Neoplasms (1) · Neoplasms (1) · Neuroendocrine Tumors (1) · Postural Orthostatic Tachycardia Syndrome (1) · Prostatic Neoplasms (1) · Recurrence (1)
National Cancer Institute (NCI) (2) · Danbury Hospital (1) · Eastern Cooperative Oncology Group (1) · Radboud University Medical Center (1) · Satish R. Raj (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of California, San Francisco (1)
United States (7) · Canada (1) · Netherlands (1)
Abhijith Hegde, MD (1) · Bert H. O'Neil, MD (1) · Charles Ryan, MD (1) · Joost Drenth, MD PhD (1) · Kevin C Conlon, M.D. (1) · Mary Mulcahy, MD (1) · Matthew H Kulke (1) · Satish R Raj, MD MSCI (1)
PMID 15911704, PMID 19687359, PMID 20884247, PMID 24002370, PMID 24227635, PMID 24495468, PMID 24606242, PMID 24721800, PMID 29853660, PMID 32673517
U10CA023318 (1), U10CA031946 (1), U10CA180821 (1), UL1TR000445 (1)